Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Two Indiana University doctors have been awarded grants by the American Lung Association Research Institute for their ...

RILD in NHL patients presents as lung disease, organizing pneumonia, and nonspecific interstitial pneumonia, with 179 ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

50 – 80 years of age Have a 20 pack-year history of smoking (1 pack a day for 20 years or 2 packs a day for 10 years) Are a current smoker or have quit within the last 15 years If you meet the ...

Third Quarter 2024 and Subsequent Period Highlights Third Quarter 2024 Financial Highlights and Cash Position About Efzofitimod Efzofitimod is a first-in-class biologic immunomodulator in clinical ...

The following is a summary of “A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity ...

There will also be themed networking sessions, including “Meet the Editors,” where participants can discuss scientific publishing with editors from leading rheumatic disease journals. Manno also ...

Kil's inspiring journey highlights the power of organ donation and the exceptional care provided by University of Utah Health. After being diagnosed with Interstitial Lung Disease, Kil faced a ...

Although Utahns do not smoke tobacco at the rate of Americans in most states, it doesn’t mean they are not vulnerable to lung ...